Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 6/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29631094 | 1.00 | AXL (0.44) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL29368189 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL29365402 | 0.74 | AXL (0.53) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL105581 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL4037241 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL31324910 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL423202 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL29468124 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL2656577 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL104668 | 0.74 | AXL (0.53) | AXLMKNK1MKNK2PDPK1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466027-B2 | Modulators of the NMDA receptor | H. LUNDBECK A/S (DK) | 2022-10-11 | — | — | US | disclosed |
| US-11466027-B2 | Modulators of the NMDA receptor | H. LUNDBECK A/S (DK) | 2022-10-11 | — | — | US | disclosed |
| US-20220213117-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-07-07 | — | — | US | disclosed |
| US-20220213117-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-07-07 | — | — | US | disclosed |
| US-11358971-B2 | Prodrugs of modulators of the NMDA receptor | H. LUNDBECK A/S (DK) | 2022-06-14 | — | — | US | disclosed |
| US-11358971-B2 | Prodrugs of modulators of the NMDA receptor | H. LUNDBECK A/S (DK) | 2022-06-14 | — | — | US | disclosed |
| EP-3994141-A1 | MODULATORS OF THE NMDA RECEPTOR | H. Lundbeck A/S (DK) | 2022-05-11 | — | — | EP | disclosed |
| EP-3994140-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. Lundbeck A/S (DK) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022058920-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-24 | — | — | WO | disclosed |
| CN-114008054-A | NMDA receptor modulators | H.隆德贝克有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210047342-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-02-18 | — | — | US | disclosed |
| US-20210047342-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-02-18 | — | — | US | disclosed |
| WO-2021001423-A1 | MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-01-07 | — | — | WO | disclosed |
| US-20210002292-A1 | MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-01-07 | — | — | US | disclosed |
| US-20210002292-A1 | MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-01-07 | — | — | US | disclosed |
| WO-2021001423-A1 | MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-01-07 | — | — | WO | disclosed |
| WO-2021001420-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-01-07 | — | — | WO | disclosed |
| WO-2021001420-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-01-07 | — | — | WO | disclosed |
| EP-3686196-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | Hangzhou Innogate Pharma Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019182274-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO., LTD. (KR) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466027-B2 | Modulators of the NMDA receptor | GRIN1, GRIN2A, GRIN3A | AXL 3367/4885MKNK1 676/4885MKNK2 575/4885 |
| US-11358971-B2 | Prodrugs of modulators of the NMDA receptor | GRIN3A, GRIN1, GRIN2A | AXL 1865/4885MKNK1 809/4885MKNK2 784/4885 |
| US-20210002292-A1 | MODULATORS OF THE NMDA RECEPTOR | GRIN1, GRIN2A, GRIN3A | AXL 3367/4885MKNK1 676/4885MKNK2 575/4885 |
| US-20210047342-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | GRIN3A, GRIN1, GRIN2A | AXL 1865/4885MKNK1 809/4885MKNK2 784/4885 |
| US-20220213117-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | GRIN3A, GRIN1, GRIN2A | AXL 1865/4885MKNK1 809/4885MKNK2 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.